Oncocyte Corporation
0.0007 (0.18%)
Upgrade to Real-Time
Regular Market
Volume 35,857
Bid Price 0.3989
Ask Price 0.40
News -
Day High 0.4055


52 Week Range


Day Low 0.39
Company Name Stock Ticker Symbol Market Type
Oncocyte Corporation OCX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0007 0.18% 0.3998 15:00:57
Open Price Low Price High Price Close Price Prev Close
0.40 0.39 0.4055 0.3991
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
231 35,857 $ 0.3977549 $ 14,262 - 0.2418 - 1.74
Last Trade Time Type Quantity Stock Price Currency
15:00:57 100 $ 0.3998 USD


Draw Mode:

Oncocyte Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 47.43M 118.64M 78.70M $ 7.73M $ - -0.72 -0.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 9.85k 5.40%

more financials information »

Oncocyte News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OCX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.400.41460.370.3945055245,840-0.0002-0.05%
1 Month0.400.500.3650.4245646197,021-0.0002-0.05%
3 Months0.42060.500.24180.3813849356,142-0.0208-4.95%
6 Months1.031.100.24180.5822525355,434-0.6302-61.18%
1 Year1.661.740.24180.9074069416,380-1.26-75.92%
3 Years3.496.250.24182.65490,240-3.09-88.54%
5 Years3.496.250.24182.65490,240-3.09-88.54%

Oncocyte Description

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.